In 2023, Florida and Texas reported the first locally acquired cases of mosquito-transmitted malaria in nearly 20 years, highlighting the increasing migration of diseases due to climate change and raising questions about the impact on pharmaceutical development incentives. Click here for article.
Tropical Disease Priority Review Voucher Program: Created to incentivize the development of treatments for diseases like malaria and cholera, which are prevalent in low-income countries.
Market Incentives and Climate Change: Climate change may naturally incentivize pharmaceutical development for tropical diseases as they spread to wealthier countries, potentially making the current voucher program redundant.
Task Force Recommendation: Congress should create a task force to evaluate how climate change affects drug development and to recommend adjustments to the Tropical Disease Priority Review Voucher Program.
Adjusting Incentives: The task force should consider providing the FDA with the authority to remove diseases from the voucher program, creating different tiers of vouchers, and extending incentives to repurposed drugs and diagnostic tests.
Komentar